Immune thrombocytopenia (ITP)
itp · society: ASH
← back to Hematology & Oncology
Summary
ASH 2019 guidelines provide 21 evidence-based recommendations for managing adults and children with newly diagnosed, persistent, and chronic ITP with non–life-threatening bleeding. Management options addressed include observation, corticosteroids, IVIG, anti-D immunoglobulin, rituximab, splenectomy, and TPO-RAs. Compared with the 2011 guideline, the update favors shorter corticosteroid courses, emphasizes shared decision-making for second-line therapy, and incorporates TPO-RAs as a preferred second-line option in both adults and children. The guideline does not cover diagnosis, life-threatening bleeding, pregnancy, or agents introduced after 2017.
Current guideline: ASH 2019 ITP Guideline · 
download Anki sub-deck
Versions
- 2019 · ASH — ASH 2019 ITP Guideline